舊版回顧

浙江大學醫學院-斯坦福大學聯合招收博士后計劃項目招聘啟事

編輯:admin 時間:2019年05月08日 訪問次數:1232

一、 招聘崗位

崗位一

研究方向:醫學X射線定量成像及醫學影像深度分析

合作導師(浙江大學)及團隊簡介:

    牛田野,浙江大學轉化醫學研究院和附屬邵逸夫醫院雙聘教授、博導,浙江省海外高層次人才引進計劃特聘專家,科技部863計劃“青年科學家”,美國新澤西州立大學羅格斯分校放射腫瘤學系兼職副教授、美國應用臨床醫學物理期刊(SCI收錄)編委、美國醫學物理與工程類頂級期刊Physics in Medicine & Biology期刊(SCI收錄)國際咨詢委員、中國生物醫學工程學會醫學物理分會和精準放療技術分會委員。其團隊主要從事多學科交叉的醫學工程研究,致力于設計圖像定量化分析技術用于臨床腫瘤治療評估,包括基于臨床病例數據集的腫瘤治療療效評估、超低劑量雙能CT用于人體組織精準識別等。

合作導師(斯坦福大學)及團隊簡介:

    邢磊,斯坦福大學醫學院放射腫瘤學系教授,Jacob Haimson講席教授,放射腫瘤系醫學物理學部主任,美國醫學物理學會院士,電子工程系客座教授。分子影像、Bio-X和癌癥生物學項目成員。其團隊致力于醫學物理和醫學影像技術的研究和應用,創建和領導了國際上第一個集成醫學物理、納米醫學和分子影像的研究中心,該中心也是第一個把放射腫瘤治療學與分子影像學相結合的轉化研究中心。

聯合招收博士后工作計劃:

    第一年,在浙江大學牛田野教授課題組開展醫學成像和圖像處理的研發工作,設計X射線斷層功能成像方法,構建成像-治療一體化數據分析評估體系。第二年,在斯坦福邢磊教授課題組深入研究功能成像在臨床治療引導和評估中的作用,構建腫瘤治療的多模態影像評估系統。


崗位二

研究方向(1):胃腸道腫瘤的靶向及免疫治療的轉化醫學研究

研究方向(2):長壽的轉化醫學研究

合作導師(浙江大學)及團隊簡介:

    閔軍霞,腫瘤學博士,博士生導師,浙江大學轉化醫學研究院特聘教授。2006年美國密蘇里哥倫比亞大學生物學博士;2006-2010年哈佛大學醫學院醫學遺傳系博士后;2010-2014年任諾華(Novartis,美國)腫瘤部新藥研發團隊負責人,主要負責整合分析多種組學大數據發現腫瘤新型分子靶標及CAR-T的優化研究。 2014年加盟浙江大學醫學院并入選浙江省海外高層次“浙江省千人”創新學者及“浙江省特聘專家”。多年來主要運用醫學及生命科學前沿技術開展腫瘤的轉化醫學研究。在Nature Medicine、Hepatology、PNAS等著名期刊發表論文40余篇,多次應邀在國內外學術大會及著名大學院所進行主旨報告。先后承擔國家自然科學基金項目及科技部國家重點研發計劃等。更多信息請見閔軍霞老師個人主頁:https://person./Junxia

合作導師(斯坦福大學)及團隊簡介:

    程震教授,現為美國斯坦福大學分子影像中心腫瘤分子影像化學實驗室主任,斯坦福大學醫學院分子影像中心、克萊瑞-斯坦福癌癥早期檢測研究中心、斯坦福癌癥研究所、放射科及BioX中心副教授。長期從事腫瘤分子影像技術、多模態分子探針的研制和開發, 至今發表論文230余篇, H-因子61,引用超過12800次(Google學術)。程震教授在腫瘤分子影像探針及納米藥物研發及轉化方面研究成果卓著。

聯合招收博士后工作計劃:

    第一年,在浙江大學開展消化系統腫瘤的靶點篩選、分子機制、信號網絡及代謝調控等研究工作。第二年,在斯坦福大學進一步深入研究腫瘤靶向及免疫治療的分子機制及精準治療新策略。完成論文撰寫并在高水平期刊上發表研究成果。


研究方向(3):功能化納米探針的研發及其在腫瘤分子影像及治療中的應用

合作導師(浙江大學)及團隊簡介:

    周民研究員,惡性腫瘤預警與干預教育部教育部重點實驗室副主任。曾長期在美國安德森癌癥中心從事分子影像及納米醫學領域的研究工作。其團隊主要研究工作為醫學分子影像探針設計合成、智能納米載體材料在預臨床研究及臨床轉化,特別是多功能納米藥物用于癌癥及感染性疾病的治療和早期診斷,并取得了一系列的創新性結果。更多信息請見周民老師個人主頁:https://person./mi。

合作導師(斯坦福大學)及團隊簡介:

    Sanjiv Sam Gambhir教授,美國醫學科學院院士、斯坦福大學醫學院放射學系主任、分子影像中心主任。在Science、Nat Biotechnol、Nat Med、Nat Nanotechnol、Nat Method、Ca-Cancer J Clin等國際頂級期刊發表論文600余篇,是分子影像學領域的國際領軍專家。其團隊主要研究方向是分子影像探針的研發,在腫瘤的早期檢測、早期成像及治療方面處于國際頂尖水平,特別是在藥物的臨床轉化和應用領域有著卓著的成績。詳見Gambhir教授個人主頁:https://profiles.stanford.edu/sanjiv-gambhir.

聯合招收博士后工作計劃:

    第一年:在浙江大學周民研究員課題組開展分子影像探針的研發工作,設計具有多功能拉曼及其他功能的分子影像探針,構建拉曼為基礎的診療一體化納米藥物,并考察其各理化性質。第二年:在斯坦福大學Gambhir教授課題組深入研究分子影像探針在腫瘤及其他疾病領域的生物學評價及開展預臨床實驗。


崗位三

研究方向(1):神經元樹突發育與退行的分子機制研究

合作導師(浙江大學)及團隊簡介:

    鄒煒,浙江大學“百人計劃”研究員、浙江大學醫學院附屬第四醫院特聘教授。其團隊主要研究方向包括:(1)神經元樹突發育的分子機理;(2)神經退行的分子機制;(3)抑制神經退行的小分子化合物篩選及其功能研究。多項原創性研究工作發表于Developmental Cell和eLIFE等本領域國際著名學術雜志。更多信息請見鄒煒老師個人主頁:https://person./weizou

合作導師(斯坦福大學)及團隊簡介:

    沈康,斯坦福大學生物系終身教授、霍華德休斯醫學研究所研究員。其團隊主要研究方向是:(1)突觸發育的分子機制;(2)突觸囊泡轉運的分子機制;(3)神經元微管極性建立和維持的分子機制。(4)神經元樹突形態建成的分子機制。更多信息請見沈康老師的研究組主頁:http://web.stanford.edu/group/shenlab/cgi-bin/shenlab/

聯合招收博士后工作計劃:

    第一年:在浙江大學鄒煒研究員課題組開展遺傳學篩選、基因定位和克隆、突變體表型分析等工作,鑒定新穎的樹突發育和神經退行調控因子。第二年:在斯坦福大學沈康教授課題組利用先進的超分辨顯微成像、單細胞轉錄組分析等技術,深入研究新調控基因的分子機制。


研究方向(2):基于CRISPR-Cas9系統的基因技術研發與運用

合作導師(浙江大學)及團隊簡介:

    陳寶惠,浙江大學基礎醫學院“百人計劃”研究員,雙聘于浙大附屬第一醫院,博士生導師。陳寶惠研究員致力于開發基因組動態成像技術,并結合基因組編輯,探索四維基因組如何在發育、環境響應與疾病發生過程中執行功能。近年來在利用CRISPR-Cas9系統實現活細胞基因組動態成像領域取得一系列進展,以第一作者或通訊作者身份發表論文于Cell, Nucleic Acids Research, Nature Communications等國際著名雜志上。更多信息請見陳寶惠博士的個人主頁:https://person./chenlab2017

合作導師(斯坦福大學)及團隊簡

    亓磊(Stanley Qi),斯坦福大學生物工程系和化學與系統生物系教授。其團隊主要致力于合成生物學、基因技術研發和細胞治療方向的研究。近年來取得了一系列突破性進展,主要包括首次將Cas9分子開發改造為核酸酶沉默的dCas9分子,并利用dCas9開發了一系列技術,包括:基因沉默技術CRISPRi、基因激活技術CRISPRa、3D基因組重建技術CRISPR-GO和多基因表達調控及多基因神經元分化篩選系統。擁有專利20多項。在國際刊物Cell、Nature及子刊發表多篇論文,論文引用近萬次。亓磊博士獲得多項榮譽,包括NIH Director’s Early Independence Award, Pew Biomedical Scholar, Alfred. P. Sloan Scholar.更多信息請見亓磊博士的研究組主頁:http://med.stanford.edu/qilab.html

聯合招收博士后工作計劃:

    第一年:在浙江大學陳寶惠研究員課題組開展基于CRISPR-Cas9系統的新技術研發。第二年:在斯坦福大學亓磊教授課題組開展基因治療研究。


二、 崗位要求

    1、近三年內獲得國內C9高校或第四輪學科評估A+學科或海外頂尖大學博士學位;

    2、身體健康,年齡不超過32周歲;

    3、有良好的學術表現及學術發展潛力,未來有志于到浙江大學從事教學科研工作。


三、 工作方式及待遇

    每個崗位招聘1人。入選者在雙方合作導師指導下開展研究工作,根據浙江大學博士后管理工作規定完成相應的考核,完成研究工作并達到相應學科的博士后出站要求后辦理出站。在海外合作發表的學術論文及其他成果可認定為出站成果,鼓勵入選者與海外高水平研究人員和合作教授聯合發表論文,第一署名單位及排名不計先后。

項目資助期為2年,學校、學院和合作導師給予每人26-28萬/年的資助。入選者公派赴斯坦福大學工作期間,學校再給予每人10萬元補充資助,其他補充資助視情況再定。入選者在資助期內享受學校學科博士后相關福利。

    入選者在聘期內學術能力和業績表現優秀者,出站后可申請學校“百人計劃”或特聘研究員崗位,進入浙江大學預聘師資隊伍。


四、 應聘程序

    發送個人簡歷(包括個人基本信息、學習工作經歷、參與科研項目、科研成果),代表性論文及其他能證明科研能力的材料至聯系人郵箱,經面試小組綜合評估通過后報浙江大學審批。經學校批準錄用人員,須登錄中國博士后網注冊,并按浙江大學博士后進站程序辦理進站。


本次招聘報名截止日期:2019年6月8日

聯系人:常老師

聯系電話:+86-571-88981338

E-mail: changle196@



Joint Postdoctoral Fellowship Program: Zhejiang University School of Medicine and Stanford University


I. Position

Position 1

Research Area: Medical X-ray quantitative imaging and deep analysis

Supervisor at Zhejiang University:

NIU Tianye, jointly employed full professor at Institute of Translational Medicine and Sir Run Run Shaw Hospital, Zhejiang University, Ph. D. supervisor, Ministry of Science and Technology 863-Plan “Young Scientist”, adjunct associate professor at Department of Radiation Oncology, the State University of New Jersey, Rutgers, editorial board of Journal of Applied Clinical Medical Physics (SCI), international advisory committee of Physics in Medicine & Biology (top medical physics SCI journal), committee of the Medical Physics and Precision Radiotherapy Technology Branch of Chinese Society of Biomedical Engineering (CSBE). His group is mainly engaged in multidisciplinary medical engineering research, dedicated to the design of image quantitative analysis technology for clinical tumor treatment evaluation, including tumor treatment response evaluation based on clinical case dataset, ultra-low dose dual energy CT for human tissue precision identification, etc.

Supervisor at Stanford University:

XING Lei is currently the Jacob Haimson Professor of Medical Physics and Director of Medical Physics Division of Radiation Oncology Department at Stanford University. He also holds affiliate faculty positions in Department of Electrical engineering, Bio-X and Molecular Imaging Program at Stanford. Dr. Xing’s research has been focused on medical imaging, artificial intelligence in medicine, treatment planning, image guided interventions, nanomedicine, and applications of molecular imaging in radiation oncology. He has made unique and significant contributions to each of the above areas. Dr. Xing is an author on more than 300 peer reviewed publications, a co-inventor on many issued and pending patents, and a co- investigator or principal investigator on numerous NIH, DOD, RSNA, ACS and corporate grants. He is a fellow of AAPM (American Association of Physicists in Medicine) and AIMBE (American Institute for Medical and Biological Engineering). He is a recipient of Google Faculty Scholar Award. He is also on the editorial boards of a number of journals in medical physics and medical imaging.

Work Plans (Tentative Schedule):

Year 1: Conduct research on medical imaging and image processing and design the computed tomography image reconstruction scheme in the Professor Niu’s group at Zhejiang University;

Year 2: Develop the tumor evaluation system based on multimodalities images with the assistance from the research group of Professor Xing Lei from Stanford.


Position 2

Research Area (1): Translational medical research of gastroenterology cancer

Research Area (2): Translational medical research of longevity

Supervisor at Zhejiang University:

Junxia Min M.D., Ph.D. currently serves as a professor at Institute of Translational Medicine & The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Prof. Min earned her Ph.D. from University of Missouri-Columbia in the United States in 2006. The key finding during her PhD training was discovered the important roles of sphingolipid metabolic pathway in cancer treatment. From 2006-2010, Dr. Min had her postdoctoral training at the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School. She identified the important novel epigenetic regulatory mechanisms in tumorigenesis. Since 2010, Dr. Min joined Novartis Department of Oncology as a group leader at Boston, U.S.A., where her group discovered and functionally validated several novel targets for further clinical drug development. In aging research area, Prof. Min has been co-leading genetic contributions of the world largest centenarian cohort “The Chinese Longitudinal Healthy Longevity Study (CLHLS)”. Based on this 20-year longitudinal cohort study, the team has uncovered key genetic factors that associated with longevity.

Supervisor at Stanford University:

Prof. Zhen Cheng serves as the Director of Molecular Imaging Program at Stanford (MIPS) (2007 - Present) and member of Bio-X Program, Stanford Cancer Center, and Canary Center at Stanford for Cancer Early Detection (2009 - Present). Cheng lab has been working on identification of novel cancer biomarkers with significant clinical relevance, to develop new chemistry for probes preparation, and to validate new strategies for probes high-throughput screening. The goal of Cheng laboratory is to develop novel molecular imaging probes and techniques for non-invasive detection of cancer and its metastasis at the earliest stage, so that cancer can be cured or transformed into a chronic, manageable disease. The techniques developed in Cheng research will allow a close examination of the molecular, metabolic and physiological characteristics of cancers and their responses to therapy. Prof Cheng has published over 250 research articles, H-index 61,citation >12800(Google scholar).

Work Plans (Tentative Schedule):

Year 1: Working with Prof. Junxia Min at Zhejiang University to study on identification of novel cancer therapeutic targets, molecular regulatory mechanisms, signaling networks, metabolic regulation and clinical implications of precision cancer diagnosis and treatment.

Year 2: Working with Prof. Zhen Cheng at Stanford University to explore underlying molecular mechanisms and to develop novel strategies for effective cancer therapeutics. Prepare and submit manuscripts for publication.


Research Area (3): Development of functionalized nanoprobes for molecular imaging and therapy

Supervisor at Zhejiang University:

Min Zhou received his Ph.D. degree from the Department of Chemistry at Shandong University. He worked as an Instructor at the University of Texas, MD Anderson Cancer from 2012 to 2016. Currently, he is a Professor in the Institute of Translational Medicine at Zhejiang University. His research focuses on the development of targeted imaging probes tumor imaging, new technique for real-time imaging-guided surgery, and novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents. Personal website: https://person./mi.

Supervisor at Stanford University:

Prof. Sanjiv Sam Gambhir, MD, Ph.D., is the Virginia & D.K. Ludwig Professor of Cancer Research and the Chair of Radiology at Stanford University School of Medicine. He also heads up the Canary Center at Stanford for Cancer Early Detection and directs the Molecular Imaging Program at Stanford (MIPS). He has over 600 publications in the field and over 40 patents pending or granted. His lab's work has been featured on over 30 journal covers such as Science, Cancer Cell, Nature Drug Discovery, Science Translational Medicine, and Circulation. He was elected to the Institute of Medicine of the US National Academies in 2008. An internationally recognized researcher in molecular imaging, his lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies.Personal website: https://profiles.stanford.edu/sanjiv-gambhir

Work Plans (Tentative Schedule):

Year 1: Work with Prof. Min Zhou at Zhejiang University to design nanoprobes for Raman imaging and other multimodal imaging functions to construct theranostic nanoplatforms and to investigate their physicochemical properties.

Year 2: Work with Prof. Sanjiv Sam Gambhir at Stanford University to study in vivo Raman imaging on the biological evaluation and mechanism study. Prepare and submit manuscripts for publication.


Position 3

Research Area (1): Molecular mechanisms of dendrite development and degeneration

Supervisor at Zhejiang University:

Prof. Wei Zou, Ph.D., is funded by the “100-talent plan” of Zhejiang University.  Prof. Zou focuses on (1) molecular mechanisms of dendrite morphogenesis in neurons; (2) molecular mechanisms of neurodegeneration; and (3) identification of small molecules to suppress neurodegeneration. More information can be found in https://person./weizou

Supervisor at Stanford University:

Prof. Kang Shen, Ph.D., is a Professor of Department of Biology and investigator of the Howard Hughes Medical Institute. The main research focus of Prof. Shen’s team is to identify novel molecular and cellular mechanisms underlying: (1) synapse formation; (2) axonal transport; (3) neuronal microtubule polarity; and (4) dendrite morphogenesis. More information can be found in:

http://web.stanford.edu/group/shenlab/cgi-bin/shenlab/

Work Plans (Tentative Schedule):

Year 1: Work with Prof. Wei Zou at Zhejiang University to conduct genetic screens to identify novel regulators in dendrite development and neurodegeneration in C. elegans, map and clone the genes in the genetic mutants and perform genetic pathway analysis.

Year 2: Work with Prof. Kang Shen at Stanford to study the underlying molecular mechanisms of the novel regulators during dendrite development and degeneration by combining cutting edge techniques such as super-resolution imaging and single cell RNA-seq.


Research Area (2): Development and applications of CRISPR-Cas9 systems

Supervisor at Zhejiang University:

Dr. Baohui Chen is an investigator in the Department of Cell Biology, Zhejiang University School of Medicine. Chen developed CRISPR-Cas9-based imaging techniques to visualize sequence-specific endogenous DNA in living human cells. These new techniques allow precise examinations of the dynamics and position of specific genes and regulatory DNA elements, as well as the mapping of chromatin interactions in living cells (Cell, 2013; Nucleic Acids Res., 2016; Annu Rev Biophys., 2016; Nat Commun,2018.). Her current research is focused on the genome spatiotemporal organization and its roles in gene regulation, stress response and human diseases. More information can be found in:

https://person./chenlab2017

Supervisor at Stanford University:

Dr. Stanley Qi is Assistant Professor in the Department of Bioengineering, the Department of Chemical and Systems Biology, and a core faculty member in Stanford ChEM-H Institute. He engineered the first nuclease-deactivated dCas9 molecule, and was the first to use dCas9 to develop CRISPRi (interference) and CRISPRa (activation) technologies for sequence-specific gene regulation of the genome. His lab developed CRISPR-GO (genome organization) for the 3-D control of the genome structure and nuclear architecture. His team also (co)-developed technologies including CRISPR imaging, receptor-coupled genome engineering (ChaCha), genome-wide CRISPRi/a genetic screen, and the use of CRISPR to reprogram stem cells and neuron cells. His current research is focused on developing novel technologies of genetic engineering to control, manipulate, and engineer the genetic codes of life. More information can be found in: http://med.stanford.edu/qilab.html

Work Plans (Tentative Schedule):

Year 1: Work with Prof. Baohui Chen at Zhejiang University to develop novel genome engineering technologies.

Year 2: Work with Prof. Stanley Qi at Stanford to manipulate genetic systems for cell therapy.


II. Eligibility

1. A Ph.D. degree within the recent three years from domestic C9 universities, or from “A plus” disciplines of the fourth round of national discipline assessment by China Academic Degree & Graduate Education Development Center, or from top overseas universities.

2. The applicants shall be under 32 years old, of good moral character, and in good health.

3. Good academic performance and research capability. Interested in teaching and research positions at Zhejiang University in the future.


III. Assessment requirements and Funding

One quota for each position.The selected candidates will carry out research work under the guidance of the cooperative supervisors of both universities. The candidates shall fulfill the corresponding assessments according to the post-doctoral management regulations of Zhejiang University, complete the research work, and reach the post-doctoral requirements of the corresponding disciplines. The selected candidates are encouraged to jointly publish articles with professors at Stanford University. Academic papers and other achievements published together with professors at Stanford University can be regarded as the achievements of the postdoctoral program.

The selected candidates will be funded for two years. The full salary will be 260,000-280,000 RMB per year from Zhejiang University, School of Medicine, and supervisor. An additional grant of 100,000 RMB will be supplied during the period of work at Stanford University by Zhejiang University. Selected candidates will also enjoy the benefits of the common postdoctoral program at Zhejiang University in projects application.

Qualified selected candidates may apply for the “Hundred Talents Program” or Distinguished Research Fellow (ZJU tenure track positions) after completion of the program.


IV. Application Procedures

Send a resume (including basic personal information, study and work experiences, participation in research projects, publication list, etc.), representative papers and other materials to the bottom email address. After comprehensively evaluating through interview processes and discussing with the professor at Stanford University, the result will be reported to Zhejiang University for approval. Upon successful application, the selected candidates shall finish the registration procedures and will be subject to the management of Zhejiang University.



Application Deadline:8 June,2019

Contacts

Ms. Chang

Contact numbers: +86-571-88981338

E-mail: changle196@